A phase Ib feasibility trial of response adapted neoadjuvant therapy in gastric cancer (RANT-GC)

NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US).

(2022) Arvind Dasari et al.   JOURNAL OF CLINICAL ONCOLOGY

Association of circulating tumor DNA dynamics with clinical outcomes in the adjuvant setting for patients with colorectal cancer from an observational GALAXY study in CIRCULATE-Japan.

(2022) Masahito Kotaka et al.   JOURNAL OF CLINICAL ONCOLOGY

Use of Molecular Assays and Circulating Tumor DNA in Early Stage Colorectal Cancer: A Roundtable Discussion of the Gastrointestinal Cancer Therapy Expert Group ( GICTEG )

(2021) Arturo Loaiza‐Bonilla et al.   ONCOLOGIST

Total neoadjuvant therapy ( TNT ) versus standard neoadjuvant chemoradiotherapy for locally advanced rectal cancer: a systematic review and meta‐analysis

(2021) Shuang Liu et al.   ONCOLOGIST

1415P Performance of a tumor-informed circulating tumor DNA assay from over 250 patients with over 600 plasma time points in esophageal and gastric cancer

(2021) B.M. Huffman et al.   ANNALS OF ONCOLOGY

Clinical Applications of Minimal Residual Disease Assessments by Tumor-Informed and Tumor-Uninformed Circulating Tumor DNA in Colorectal Cancer

(2021) Jun Gong et al.   Cancers

Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences

(2021) Tenna Vesterman Henriksen et al.   CLINICAL CANCER RESEARCH

NRG-GI005 (COBRA): Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer.

(2020) Van K. Morris et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment of Locally Advanced Esophageal Carcinoma: ASCO Guideline

(2020) Manish A. Shah et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant chemotherapy is superior to chemoradiation after D2 surgery for gastric cancer in the per-protocol analysis of the randomized CRITICS trial

(2020) W.O. de Steur et al.   ANNALS OF ONCOLOGY

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

(2019) Salah-Eddin Al-Batran et al.   LANCET

Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer

(2019) Thomas Reinert et al.   JAMA Oncology

CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer

(2018) Astrid E. Slagter et al.   BMC CANCER

Initial results of CALGB 80803 (Alliance): A randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer.

(2017) Karyn A. Goodman et al.   JOURNAL OF CLINICAL ONCOLOGY

Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution

(2017) Christopher Abbosh et al.   NATURE

Clinically Meaningful Use of Blood Tumor Markers in Oncology

(2016) Stefan Holdenrieder et al.   Biomed Research International

TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG)

(2015) Trevor Leong et al.   BMC CANCER

Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial

(2012) Yung-Jue Bang et al.   LANCET